|
|
|
|
| LEADER |
03482nmm a2200313 u 4500 |
| 001 |
EB000630754 |
| 003 |
EBX01000000000000000483836 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781475715200
|
| 100 |
1 |
|
|a Yacobi, A.
|e [editor]
|
| 245 |
0 |
0 |
|a Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development
|h Elektronische Ressource
|c edited by A. Yacobi, J.P. Skelly, Vinod P. Shah, L.Z. Benet
|
| 250 |
|
|
|a 1st ed. 1993
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 1993, 1993
|
| 300 |
|
|
|a XVI, 270 p. 5 illus
|b online resource
|
| 505 |
0 |
|
|a Preclinical Pharmacodynamics of Anxiolytics: Effects of Chronic Benzodiazepine Administration -- Guidelines for Development of a New Diuretic Agent -- Preclinical Pharmacodynamics of Anti-Inflammatory Drugs -- Preclinical & Clinical Pharmacokinetics -- The Role of Pharmacokinetics in the Drug Development Process -- Implementation of an Effective Pharmacokinetics Research Program in Industry -- Pharmacoepidemiology, Population Pharmacokinetics and New Drug Development -- Assessment of Pharmacokinetic Drug Interactions in Clinical Drug Development -- Clinical Pharmacodynamics -- Pharmacokinetic/Pharmacodynamic Models and Methods -- Pharmacokinetic and Pharmacodynamic Modeling Applied to Anesthetic Drugs -- Pharmacodynamic/Pharmacokinetic Relationships for Rapidly Acting Drugs (NSAIDS) in Rheumatoid Arthritis: Problems and Preliminary Solutions -- The Value of Plasma-Warfarin Measurement -- Clinical Pharmacodynamics of Cardiovascular Agents: Focus on Sudden Cardiac Death --
|
| 505 |
0 |
|
|a Rationale for the Effective Use of Pharmacokinetics and Pharmacodynamics in Early Drug Development -- The Case for Preclinical Pharmacodynamics -- Utility of Kinetic, Dynamic, and Metabolic Data in Nonclinical Pharmacology/Toxicology Studies -- Preclinical Pharmacokinetic & Pharmacodynamic Studies -- Pharmacokinetics and Drug Metabolism in Animal Studies (ADME, Protein Binding, Mass Balance, Animal Models) -- Nonclinical Considerations: Disposition of Drugs -- Use of Acute Toxicity Data in the Design and Interpretation of Subchronic and Chronic Toxicity Studies -- Use of Pharmacokinetics and Pharmacodynamics in Preclinical Studies to Guide Dosage Escalation Schemes in Phase I Studies of Anticancer Drugs -- Use of Toxicokinetic Principles in Drug Development: Bridging Preclinical and Clinical Studies -- Methodology for Preclinical Pharmacodynamic Studies -- Preclinical Pharmacodynamics of Central Nervous System Active Agents -- Preclinical Pharmacodynamics of Antihypertensives --
|
| 505 |
0 |
|
|a The Benzodiazepines: Kinetic-Dynamic Relationships -- Application of Pharmacodynamics & Pharmacokinetics in the Drug Development Process -- The Integration of Pharmacodynamics and Pharmacokinetics in Rational Drug Development -- Concentration-Controlled Trials: Basic Concepts, Design, and Implementation -- Summary Report -- Opportunities for Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development
|
| 653 |
|
|
|a Pharmacy
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Skelly, J.P.
|e [editor]
|
| 700 |
1 |
|
|a Shah, Vinod P.
|e [editor]
|
| 700 |
1 |
|
|a Benet, L.Z.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4757-1520-0
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4757-1520-0?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|